The short answer is careful. In UK guidance, nabilone has a specific role for chemotherapy-induced nausea and vomiting when conventional anti-sickness treatment has not controlled symptoms well enough. That does not mean medical cannabis is a general appetite, weight-gain or cancer symptom treatment, and it does not mean a patient should step outside their oncology or palliative care team.
This guide is for patients and carers who are asking whether cannabis-based medicines fit into chemotherapy nausea, vomiting, appetite loss or weight-change conversations. It is not medical advice and it cannot decide whether any medicine is suitable. During chemotherapy, that decision needs the oncology team, and sometimes a palliative care or symptom-control team, because they understand the cancer treatment plan, infection risk, hydration, nutrition, other medicines and urgent-warning signs.
If you are new to the wider prescription route, start with the MCPH patient guide. For background on the licensed cannabis medicines named in UK guidance, read licensed cannabis medicines in the UK. For safety context, keep medical cannabis side effects and medical cannabis and medication interactions close by.
The short answer
NICE NG144 says clinicians can consider nabilone as an add-on treatment for adults with chemotherapy-induced nausea and vomiting that persists with optimised conventional antiemetics. In plain English: the usual anti-sickness medicines should be properly reviewed first, and nabilone is a clinician-led option for nausea and vomiting in that specific context.
That is different from saying:
- cannabis-based products are first-line chemotherapy nausea medicines;
- medical cannabis is proven for appetite loss, cachexia or weight gain;
- a cancer diagnosis automatically means someone can access medical cannabis;
- “may qualify” language means the final clinical decision has already been made;
- a private prescription would be separate from oncology safety review;
- a patient can choose a product, dose or route from an article.
The useful question is not “Does chemotherapy qualify me for cannabis?” It is: “My nausea, vomiting, appetite or weight symptoms are not controlled. What does my oncology or palliative care team think is the safest next step, including whether nabilone has a place?”
Where nabilone fits
Nabilone is a synthetic cannabinoid medicine. It is not the same thing as choosing dried cannabis flower, oil, CBD products or an unlicensed cannabis-based medicinal product.
For chemotherapy-related nausea and vomiting, the source-backed boundary is narrow:
- the symptom is chemotherapy-induced nausea and vomiting;
- conventional antiemetic treatment has been reviewed and optimised;
- symptoms are still a problem;
- the decision is made by the treating clinical team;
- side effects and interactions are checked against the wider cancer treatment plan.
This matters because chemotherapy nausea is not just an inconvenience. Persistent vomiting can affect hydration, nutrition, kidney function, ability to take medicines, infection risk and whether treatment can continue as planned. That is why MCPH should not present nabilone as a simple cannabis-access route.
Appetite symptoms are a separate question
Appetite loss, taste changes, early fullness and weight loss can happen during cancer treatment, but they are not all the same clinical problem. Some are linked to chemotherapy side effects. Some are linked to infection, pain, constipation, mouth problems, anxiety, low mood, disease progression, swallowing problems, medicines or cachexia.
The source pack for this article does not support a broad public claim that medical cannabis treats appetite loss or reverses weight loss in cancer care. A patient may feel appetite is part of the same symptom cluster, but a clinician still needs to assess what is causing it and what the safest support is.
Useful support may include anti-sickness review, mouth-care advice, constipation review, dietitian input, nutritional supplements, steroid or other medicine review, infection checks, pain control, or palliative care symptom review. Cannabis-based medicines should not be presented as the shortcut around that work.
Unlicensed cannabis-based products need a tighter boundary
Unlicensed cannabis-based medicinal products can be prescribed in the UK only within professional and legal prescribing rules. NHS England, GMC and CQC guidance all keep the prescriber boundary central: suitability depends on the patient, the condition, previous treatments, evidence, risk, monitoring and whether licensed medicines are more appropriate.
For chemotherapy nausea and appetite symptoms, that means:
- nabilone has a clearer licensed context than unlicensed products;
- unlicensed products should not be described as routine cancer symptom treatment;
- private prescribing does not remove the need for oncology-team coordination;
- product, form, dose, route and monitoring belong with the prescriber;
- diagnosis alone does not decide access.
If a patient is already under active cancer treatment, any cannabis-based medicine discussion should include the oncology team. This is especially relevant where there are chemotherapy medicines, immunotherapy, blood thinners, sedatives, anti-sickness medicines, steroids, infection risk, frailty, falls risk, confusion, liver or kidney concerns, or complex pain medicines.
What to ask your oncology or palliative care team
Patients and carers can ask direct questions without trying to force a treatment decision.
Practical questions include:
- Are my nausea and vomiting classed as chemotherapy-induced nausea and vomiting?
- Have my conventional anti-sickness medicines been optimised, or is there another standard option to try first?
- Is nabilone relevant in my situation, or would the risks outweigh the possible benefit?
- Could my appetite or weight symptoms be caused by something that needs separate treatment?
- Are any of my current medicines a concern if a cannabinoid medicine is discussed?
- Who would monitor side effects, confusion, sleepiness, falls risk, hydration and treatment response?
- If symptoms worsen, which urgent oncology or NHS contact route should I use?
This is preparation, not self-prescribing. It helps the team understand what is happening and whether the next step is antiemetic review, nutrition support, palliative care review, nabilone, another medicine, investigation, or urgent assessment.
Safety issues are not secondary
Nabilone and other cannabinoid medicines can cause side effects such as sleepiness, dizziness, changes in mood, confusion, dry mouth, impaired attention and feeling unsteady. During chemotherapy, those effects can matter more because patients may already be tired, dehydrated, anaemic, taking sedating medicines, or at risk of falls.
Medicine interactions also matter. NHS medical cannabis guidance says CBD and THC can affect how other medicines work. In cancer care, that is a reason for pharmacist and clinician review, not a reason to panic. The useful action is to give the team a full list of prescription medicines, over-the-counter medicines, supplements, non-prescribed cannabinoid products, alcohol use and any previous cannabis reactions.
If nausea or vomiting is severe, if you cannot keep fluids down, if there is fever, new confusion, severe drowsiness, chest pain, severe abdominal pain, blood in vomit or stool, black stool, fainting, dehydration, or a symptom your chemotherapy team has told you to treat as urgent, use the urgent contact route you have been given or an appropriate NHS urgent-care route.
What this means in plain English
Nabilone is the cannabis-linked medicine with the clearest UK place in chemotherapy nausea and vomiting. Even then, it sits after optimised conventional anti-sickness care and inside oncology-led review.
Medical cannabis should not be used as a broad headline for appetite, weight, cachexia or palliative symptom control. Those symptoms deserve serious assessment, and sometimes urgent assessment, because the cause matters.
For patients and carers, the next step is simple: describe the symptoms clearly, ask whether conventional antiemetics have been reviewed properly, ask whether nabilone is relevant, and keep the cancer team involved in any cannabis-based medicine discussion.
FAQ
Is nabilone medical cannabis?
Nabilone is a synthetic cannabinoid medicine with a specific licensed role in chemotherapy-induced nausea and vomiting. It should not be treated as the same thing as unlicensed medical cannabis products, CBD products, cannabis flower or oils.
Does chemotherapy nausea mean I may qualify for medical cannabis?
No. Chemotherapy nausea does not automatically decide access. NICE guidance supports clinician consideration of nabilone as an add-on option when nausea and vomiting persist despite optimised conventional antiemetics. Suitability remains a clinical decision.
Can medical cannabis help appetite during chemotherapy?
This guide does not make that claim. Appetite loss and weight change need clinical review because they can have several causes. The current source base does not support a broad public claim that medical cannabis treats appetite loss or cachexia in cancer care.
Should I talk to a private cannabis clinic before my oncology team?
If you are receiving chemotherapy, your oncology team should be part of the conversation. A private specialist assessment should not sit in isolation from active cancer treatment, interactions, infection risk, monitoring and urgent-care planning.
Can this article tell me which product or dose to ask for?
No. Product, form, dose, route, monitoring and whether any cannabinoid medicine is suitable belong with the prescriber and the cancer care team.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NHS. Chemotherapy. https://www.nhs.uk/tests-and-treatments/chemotherapy/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
- CQC. Cannabis-based medicinal products: what CQC expects providers to know. https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
- MHRA. Supply unlicensed medicinal products: specials. https://www.gov.uk/government/publications/supply-unlicensed-medicinal-products-specials
Cover image brief: cover-brief.md.
